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Abstract
Smoking is an important environmental factor in 
inflammatory bowel disease (IBD), having different 
effects in ulcerative colitis (UC) and Crohn’s disease 
(CD). A recent meta-analysis partially confirmed previous 
findings that smoking was found to be protective against 
ulcerative colitis and, after onset of the disease, might 
improve its course, decreasing the need for colectomy. 
However, smoking increases the risk of developing Crohn’
s disease and worsens its course, increasing the need 
for steroids, immunosuppressants and re-operations. 
Smoking cessation aggravates ulcerative colitis and 
improves Crohn’s disease. Data are however, largely 
conflictive as well as the potential mechanisms involved 
in this dual relationship are still unknown. In this 
review article, the authors review the role of smoking in 
inflammatory bowel diseases. 
© 2007 WJG. All rights reserved.
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INTRODUCTION
The pathogenesis of  ulcerative colitis (UC) and Crohn’s 
disease (CD) has only been partly understood. Inflammatory 
bowel disease (IBD) is a multifactorial disease with probable 
genetic heterogeneity[1,2]. In addition, several environmental 
(eg, diet, smoking, measles or appendectomy) risk factors 
may contribute to its pathogenesis.
During the past decades, the incidence pattern of  
both diseases has changed significantly[3], showing some 
common but also quite distinct characteristics for the 
two disorders. Differences in geographic distribution, 
and particularly changes in incidence over time within 
one area, may provide insight into possible etiological 
factors[4]. It is very unlikely however, that these rapid 
changes attributed to variations in the genetic factors. On 
the contrary, environmental factors are likely to play an 
important role. Diet, as a luminal antigen, was thought to 
be an important factor in the pathogenesis of  IBD[1,5]. In 
the last two decades, there has been a shift in the lifestyle 
in Eastern Europe, Asia, and Central America, as the 
lifestyle, including the diet, became more “Westernized”. 
This possibility is further supported by the differences in 
incidence and prevalence found within one region.
A further important environmental factor studied 
extensively in both diseases is smoking. The link between 
smoking and (IBD) was first made in 1982 when Harries 
et al [6] noticed a low proportion of  ulcerative colitis 
patients were smokers. Two years later a case-control 
study by Somerville et al[7] reported that the relative risk of  
developing Crohn’s disease was 4.8 in those who smoked 
before disease onset, and 3.5 for those with a current 
smoking habit. In recent years, IBD has been classified 
into subtypes/phenotypes that are distinct and based 
on age at onset, disease location, and clinical behaviour. 
Knowledge of  this heterogeneity has led to the re-
examination of  genetic and environmental influences on 
IBD. The relationship between smoking and IBD however, 
is far more complex than previously realized as clinical 
subtypes have become apparent. In this article, the authors 
give an updated review on the role of  smoking in IBD.
EFFECT OF SMOKING CESSASION AND 
SMOKING ON THE RISK OF DEVELOPING 
INFLAMMATORY BOWEL DISEASES
Risk for developing ulcerative colitis 
Ulcerative colitis affects predominantly non-smokers 
and former smokers. The percentage of  current smokers 
(smoking more than seven cigarettes per week) in a 
group of  patients with UC is about 10%-15%[8,9]. These 
percentages are significantly lower than those observed in 
a control population matched for sex and age (25%-40%). 
The meta-analysis by Calkins[10], conducted more than 15 
years ago, yielded a pooled odds ratio of  0.41 (0.34-0.48) 
for current smokers compared with lifetime non-smokers. 
The effect of  smoking seems to only postpone the event, 
as the relative risk of  UC was also higher in former 
smokers (OR: 1.64; 95% CI: 1.36-1.98). In a recent meta-
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analysis by Mahid et al[11] comparable values were reported, 
which also included new available data. Current smoking 
decreased the risk for UC (OR: 0.58; 95% CI: 0.45-0.75), 
while former smoking was associated with an increased 
risk (OR: 1.79; 95% CI: 1.37-2.34). Interestingly, in 
patients who stopped smoking, UC developed in 52% of  
patients, in the first three years after cessation, as reported 
by Motley et al[12] in concordance with other studies[13]. In 
contrast, active smoking in early childhood was associated 
with a gradually increased risk for developing UC (OR for 
smoking start < 10 years: 7.02 and < 15 years: 3.46)[14]. 
The same trend was observed for passive smoking by the 
mother (OR: 1.53, 95% CI: 0.93-2.49).
The relationship between smoking and ulcerative 
colitis has also been examined at a population level. The 
prevalence of  UC was five-fold increased in patients from 
the Mormon Church in Britain and Ireland, where smoking 
is strongly discouraged, compared with that of  the general 
population. In contrast, CD was equally as common[15]. In 
addition, a review of  56 epidemiological studies in Sweden 
over the time period from 1930 to 1990[16] demonstrated 
that the sex distribution of  UC had changed from an 
earlier female predominance to a later male predominance. 
Over the same period, the proportions of  smokers and 
ex-smokers among men and women have undergone 
reciprocal changes with an increase in women smokers 
relative to men, while the same change in predominance 
was not observed in contemporary pediatric studies. 
Somewhat contradictory, in a recent population-based 
case-control study[17], among others, ever smoking was also 
associated with increased risk (1.66; 95% CI: 1.17-2.35).
There are only very few data regarding the effect of  
smoking in indeterminate colitis[8,18]. The effect seems 
to be similar to that observed in UC, that is, a protective 
effect against the development of  colitis and a possible 
beneficial effect on disease course.
Risk for developing Crohn’s disease
The percentage of  current smokers in a group of  patients 
with CD is significantly higher than that observed in a 
control population matched for sex and age (45%-55% vs 
30%-40%)[19]. In concordance, an increased life-time risk 
was reported in current smokers when compared to non-
smokers by both Calkins et al[10] (OR: 2.0; 95% CI: 1.65-2.47) 
and in the more recent meta-analysis by Mahid et al (OR: 
1.76; 95% CI: 1.40-2.22).
Compared to never-smokers, former smokers were 
reported to have an increased risk of  developing CD[10]. 
This risk decreased only after four years of  having quit 
smoking. In a recent population-based study by Bernstein 
et al[19], similar data were reported, both current smoking 
(OR: 1.96) and ever smoking (OR: 1.78) were associated 
with increased risk to develop CD. However, this later 
association could not be replicated in the recent meta-
analysis by Mahid et al although a trend was observed 
(P = 0.08). In contrast, ever smoking was associated with 
increased risk (OR: 1.61; 95% CI: 1.27-2.03). The effect 
of  passive smoking remains controversial[20]. In one recent 
prospective study[14] CD patients were more likely than 
controls to have prenatal smoke exposure (OR: 1.72; 95% 
CI: 1.1-2.71). In addition, the passive smoke exposure 
during childhood, with parents or other household 
members being smokers (OR: 2.04; 95% CI: 1.28-3.31) 
was also associated with increased risk, in concordance 
with previous data by Lashner et al[21]. 
EFFECT OF SMOKING AND ITS
CESSATION ON DISEASE PHENOTYPE
AND COURSE
Effect of smoking and its cessation on clinical course and 
extent of ulcerative colitis
Although the extent at diagnosis is not affected by 
smoking, UC usual ly r uns a more benign disease 
course in smokers compared to non-smokers. Flare-up, 
hospitalization rates[13], the need for oral steroids[22] and 
colectomy rates[22,23], are reported to be lower, while age 
at onset is older in smokers compared to non-smokers, 
though not in all studies. Relapse rates are lower in patients 
who began smoking after the diagnosis of  UC [24]. In 
concordance, in a recent Europe-wide population-based 
cohort[25] the relapse rate was lower (Hazard Ratio: 0.8; 
95% CI: 0.6-0.9) in smokers compared to non-smokers, 
while it was higher in women. In a retrospective analysis 
of  a large series of  patients with UC, current smoking 
was found to decrease the 10-year cumulative colectomy 
risk from 0.42 to 0.32[22]. In concordance, a meta-analysis 
of  several large series with a total of  1489 UC patients 
also found the risk for colectomy to be lower (OR: 0.57; 
95% CI: 0.38-0.85) in current smokers compared to non-
smokers[26].
In addition, in smokers with distal UC at diagnosis, 
the proximal extension of  the disease is less frequent[22,27], 
while primary sclerosing cholangitis is observed almost 
exclusively in non-smokers[28]. Disease regression[29] was 
also more likely to occur in smokers compared to non-
smokers or ex-smokers 5 years (30% vs 5% vs 8%), but 
not 10 years after the diagnosis. Also, those with extensive 
disease were the lightest smokers, whereas those with 
healthy colons were the heaviest smokers. Finally, current 
smokers have a lower incidence of  pouchitis following 
coloproctectomy with ileal reservoir when compared to 
non-smokers[30,31].
In contrast, intriguing new data by Aldhous et al[29] 
showed that current and non-smokers had an almost 
identical age at onset (31.1 vs 29.4 years) and this was 
delayed only in ex-smokers (46.5 years). Colectomy rates 
were not different. This group however, had a greater 
exposure to smoking compared to the group of  current 
smokers.
A link between smoking habits and the course of  UC 
has also been reported. In intermittent smokers, many 
patients note symptom exacerbation when they stop 
smoking, followed by symptom relief  when they smoke 
again[12]. In contrast, almost half  of  the intermittent 
smokers thought that their colitis symptoms improved 
while smoking at least 20 cigarettes per day[32]. Moreover, 
smokers with UC who quit, experience an increase in 
disease activity, hospital admissions, and the need for major 
medical therapy (oral steroids, immunosuppressants), 
within the first years following the cessation of  smoking[33]. 
However, the risk of  colectomy in the short-term was 
not increased compared to matched non-smokers and 
continuing smokers.
Effect of smoking and its cessation on disease location, 
behaviour, and disease progression in Crohn’s disease
Smoking is associated with disease location: most, but not 
all, studies report a higher prevalence of  ileal disease and a 
lower prevalence of  colonic involvement in smokers[34-36].
A recent review[36] and previous data have demonstrated 
that smoking, when measured up to the time point of  
disease behavior classification, was associated more 
frequently with complicated disease, penetrating intestinal 
complications[34,37,38], and greater likelihood to progress 
to complicated disease, as defined by development of  
strictures or fistulae[36], and a higher relapse rate[2,39]. Of  
note, previous severity of  the disease, as assessed from 
the therapeutics needs, was found to be similar in young 
patients who started smoking and in their matched 
controls[10]. The need for steroids and immunosuppressants 
is increased in smokers compared to non-smokers[35]. 
Whether the daily dose (eg, more than 15 cigarettes per 
day) or the total pack years smoked is more important in 
the abovementioned associations remains questionable.
The risk of  surgery as well as the risk for further 
resections during disease course is also higher in smokers, 
in most studies[34,41,42]. These findings were reinforced 
by Cottone et al[43] who have shown that macroscopic 
lesions on the ileal site of  the anastomosis were observed 
1 year after surgery in 70% of  smokers, versus 35% 
of  non-smokers and 27% of  ex-smokers. The risk of  
symptomatic postoperative recurrence was more marked 
in heavy smokers than in mild smokers[43]. Noteworthy, 
immunosuppressive therapy was found to neutralize the 
effect of  smoking on the need for surgery[40].
However, the harmful effect of  smoking on the course 
of  CD is not a universal finding. Studies in patients from 
Israel and Hungary have not found differences in the need 
for surgery or for immunosuppressants between smokers 
and non-smokers[2,44,45], and patients with only colonic 
involvement are less sensitive to the harmful effects 
of  smoking[8]. Finally, the development and severity of  
perineal complications do not seem to be influenced by the 
smoking status[39].
In a recent paper by Aldhous et al[46] using the Montreal 
classification, the harmful effect of  smoking was only 
partially confirmed. Although current smoking was 
associated with less colonic disease, the smoking habits at 
diagnosis were not associated with time to development 
of  stricturing disease, internal penetrating disease, 
perianal penetrating disease, or time to first surgery. Age 
at diagnosis was also similar in current smokers and non-
smokers (28.3 years and 28.9 years) and was only delayed 
in ex-smokers (43.2 years). However, the way in which they 
measured tobacco exposure was different from previous 
studies. “Current smokers” were defined as those who 
were smoking at the time of  diagnosis or event (penetrating 
or stricturing complication) and “ex-smokers” had stopped 
for at least one year before the diagnosis or event (eg, a 
patient could have continued smoking up to 1 year before 
developing a complication but was considered an “ex-
smoker”).
The rationale for this may be that after surgery, the risk 
of  endoscopic and clinical recurrence in former smokers 
who have not smoked for at least 1 year is similar to that 
of  non-smokers[43]. Similarly, CD activity in ex-smokers is 
not different from that of  non-smokers, and is less marked 
than in current smokers[39]. The beneficial effect of  quitting 
smoking might be seen within the year following cessation. 
A large prospective intervention study by Cosnes et al[47] 
performed in a selected group of  59 patients who stopped 
smoking following a smoking cessation intervention, 
examined the disease course from 1 year following 
smoking cessation onwards. The flare-up rate, therapeutic 
needs, and disease severity were similar in patients who 
had never smoked and in those who stopped smoking, and 
both had a better course than current smokers. Quitters 
had a 65% lower risk of  flare-up compared to continuing 
smokers. The need for corticosteroids, immunosuppressive 
therapy, or a dose increase of  immunosuppressants was 
also lower. Interestingly, after quitting, some patients 
developed UC-like lesions of  the distal colon, whereas 
previously they had typical CD.
Finally, in a prospective study during pregnancy, the 
improvement of  disease activity was observed only in 
smokers, in parallel with a decrease in the daily cigarette 
smoking[48]. 
The role of gender, familial disease, and ethnicity
The effect of  smoking is to some extent different between 
male and female patients. In CD, women are affected more 
drastically by smoking. The relative risk associated with 
smoking for women may be greater than for men: one 
study demonstrated a three-fold difference[20].
This was already demonstrated by Sutherland et al[42] in 
1990, who reported that in a group of  174 patients who 
required surgery for Crohn’s disease, smokers had a 29% 
greater risk than non-smokers, over 10 years. However, the 
increased risk was more marked in females than males (OR: 
4.2; 95% CI 2.0-4.2 in females and 1.5; 95% CI 0.8-0.6 in 
males). In Crohn’s colitis, smoking is clearly harmful for 
women, whereas colitis in men is not affected by smoking[8]. 
In the study by Cosnes et al current smoking hastened 
disease onset (from 35 to 29 years of  age) and increased the 
need for immunosuppressants, only in women.
In UC, current and ex-smoking delayed disease onset 
in men (from 25 to 42 years of  age), but not in women[50]. 
Similarly, when compared to non-smokers, male UC 
patients who smoked ran a more benign disease course as 
assessed by the decreased need for immunosuppressive 
therapy (8% vs 26%), whereas this difference was not 
observed in females as reported by Cosnes et al[8] and again 
smoking delayed the onset of  disease, only in males.
Thus, the effect of  smoking in both UC and CD seems 
to be modulated by gender, with women being affected 
more disadvantageously than men. This phenomenon 
deserves even more attention, since smoking habits are 
changing in the Western population, with a trend to a 
greater prevalence of  smokers among young women[50]. 
A gender difference in smoking habits may be a possible 
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explanation, since women use more filtered cigarettes and 
lighter cigarettes, and might consequently have a higher 
relative exposure to smoke than to nicotine[51]. In addition, 
the negative effect of  estrogens[52] on proinflammatory 
cytokine gene regulation and lymphocyte interactions 
might also play an important role.
In Israel, no association was reported between 
smoking and CD in Jewish patients, although the opposite 
association was found for UC[53]. Similarly, smoking was 
not associated to the risk for CD in some studies from 
Asia[54]. The reason why CD in Israeli Jews or Koreans is 
not as sensitive to smoking as in other populations is not 
clear. Explanations might include differences in genetic 
and/or environmental factors (eg, type of  tobacco, way of  
smoking or other alimentary factors).
A further interesting question is whether the effect of  
smoking is similar in familial versus sporadic cases. Family 
studies have reported a high concordance rate within 
families, between smoking habits and the phenotype 
of  IBD, CD developing in smokers, and UC in non-
smokers[55]. The above association was refined in more 
recent studies. Tuvlin et al[56] reported that ex-smokers 
made up an increasing percentage of  older patients 
diagnosed with UC, accounting for more than 35% of  the 
attributable risk of  late onset (> 45 years) UC and a large 
component of  the second peak in diagnosis. In contrast, 
current smoking accounted for a large percentage of  
patients diagnosed at a younger age with familial CD but 
not with sporadic CD (Table 1).
MECHANISMS BEHIND THE EFFECT OF 
SMOKING ON IBD
The reason behind the opposite effects of  smoking 
observed in CD and UC remain obscure. The effects 
of  smoking and nicotine are numerous and since the 
pathogenesis of  inflammatory bowel disease is only partially 
understood, any discussion on the possible mechanisms 
can only be speculative. In addition, although nicotine is 
thought to be the most important agent responsible for the 
effect of  smoking, one should be careful, as some effects 
usually associated with smoking may not follow the use of  
therapeutic nicotine formulations. Of  note in most studies, 
side-effects (nausea, headache, dermatitis) of  nicotine 
therapies were frequent and tended to be greater than the 
clinical benefit[57].
Smoking has numerous specific and non-specific 
effects. It has been shown to affect the immune system, by 
influencing cellular and humoral immunity. Nicotine has 
been shown to decrease the synthesis of  proinflammatory 
molecules, for example, interleukin (IL)-1β and TNFα by 
mouse colonic mucosa as well as the production of  mucosal 
eicosanoids[58] and some proinflammatory cytokines by 
human mononuclear cells (eg, IL-2[59], IL-8, and TNFα[60]) 
partly by its action on the nicotinic acetylcholine receptor a7 
subunit. Further evidence for anti-inflammatory properties 
comes from a surgically-induced ileus model, where carbon 
monoxide-treated mice were shown to have three times 
higher levels of  IL-10. Macrophages from smokers express 
a selective functional deficiency in their ability to kill 
intracellular bacteria[61]. Finally, chronic exposure of  rats to 
nicotine inhibits the antibody-forming cell response, impairs 
the antigen-mediated signaling in T-cells and induces T-cell 
anergy[62]. Other effects of  nicotine or smoking on the 
intestine include the alteration of  gut motility, the reduction 
of  smooth muscle tone and contractility (modulated by 
nitric oxide)[63], decreased permeability[64], and alterations in 
the microcirculation[65], Furthermore, smoking also increases 
lipid peroxidation.
In UC, the colonic mucosal layer is thin or absent, in 
contrast to CD where it is significantly thicker[66], with 
nicotine having been shown to increase mucin synthesis[67,68]. 
Smokers with IBD have a significant reduction in mucosal 
cytokine levels, specifically, IL-1b and IL-8 in patients with 
UC, and IL-8 in patients with CD[69]. Beneficial effects of  
nicotine in active UC may be associated with a decrease 
in IL-8 expression. Hypoperfusion of  the rectum and 
of  acutely damaged colonic tissue may play an additional 
role[70]. On the contrary, in CD, several plasma antioxidant 
parameters are altered, the total radical-trapping antioxidant 
potential is decreased[71], and abnormalities are present in 
the microvasculature[65]. Smoking through increased carbon 
monoxide concentration might amplify the impairment 
in the vasodilation capacity of  chronically inflamed 
microvessels, resulting in ischemia and perpetuating 
ulceration and fibrosis[70]. Furthermore, smoking is known 
to increase the thrombotic potential associated with vascular 
damage. A defect in bacterial clearance or macrophage 
deficiency might also play an important role. 
Table 1  Smoking in IBD: Practice points
Ulcerative colitis (UC) Crohn’s disease (CD)
Current smoking decreases the risk for UC by app. 50%, in contrast former 
smoking is associated with an app. 2-fold increased risk 
Both current and former smoking (presumable also passive smoke exposure 
during childhood) increases the risk of CD almost 2-fold
The protective effect is smaller in females The risk is greater in females compared to males 
Proximal extension of the disease is less likely in smokers as well as disease 
course is milder but the risk of lung cancer and vascular disease is higher
Smoking is associated with complicated (stricturing or penetrating) and ileal 
disease
Patients who stop smoking experience an increase in disease activity at 
least during the first year after cessation
Smokers with CD need more steroids, more immunosuppressants and more 
operations than non-smokers 
The effect of smoking is similar in indeterminate colitis (less evidence is 
available)
Smoking cessation improves rapidly the course of CD
Nicotine-replacement therapies and antidepressants are useful in heavy smokers motivated to stop smoking
Geographic differences exists (e.g. Israel, Korea)
Lakatos PL et al . IBD epidemiology                                                                                                                 6137
www.wjgnet.com
CONCLUSION
In conclusion, smoking plays a dual role in IBD by 
increasing the risk for CD and decreasing that of  UC. In 
an individual who is genetically at risk for IBD, smoking 
might be an important factor in determining disease 
phenotype. In addition, smoking also affects the disease 
course. It improves UC and worsens CD, more markedly 
in women, while smoking cessation is followed rapidly by 
a reversed effect. Since smoking is associated with several 
additional deleterious effects (eg, cardiovascular, lung 
cancer risk), gastroenterologists should encourage both 
UC and CD patients to quit smoking. Before stopping, 
UC patients should be informed about the potential risk 
of  increase in disease activity, without a higher risk for 
surgery. In CD, the benefit of  smoking cessation is well-
proven, since patients who continue to smoke have a 
more severe course of  disease with more complications, 
while ex-smokers run a similar course of  disease to non-
smokers.
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